Phone:
+1 877 302 8632
Fax:
+1 888 205 9894 (Toll-free)
E-Mail:
orders@antibodies-online.com

HIV Protease antibody

Reactivity: Human Immunodeficiency Virus (HIV) ELISA, WB, Func Host: Mouse Monoclonal 1696 unconjugated
Catalog No. ABIN125709
  • Target
    HIV Protease
    Reactivity
    • 2
    • 1
    Human Immunodeficiency Virus (HIV)
    Host
    • 3
    Mouse
    Clonality
    • 3
    Monoclonal
    Conjugate
    • 3
    Un-conjugated
    Application
    ELISA, Western Blotting (WB), Functional Studies (Func)
    Specificity
    The antibody 1696 recognizes free N-terminus of mature HIV protease (HIV-1 and HIV-2), an enzyme that hydrolyzes polyproteins of HIV viruses into functional proteins. The antibody 1696 does not react with the precursor.
    Cross-Reactivity (Details)
    HIV
    Purification
    Purified by protein-A affinity chromatography.
    Purity
    > 95 % (by SDS-PAGE)
    Immunogen
    Bacterially expressed full-length HIV-1 protease
    Clone
    1696
    Isotype
    IgG1
  • Application Notes
    Functional application: The antibody 1696 strongly inhibits the enzyme activity of HIV-1 and HIV-2 proteases.
    Western blotting: Recommended dilution: 0.5 μg/mL.
    Restrictions
    For Research Use only
  • Concentration
    1 mg/mL
    Buffer
    Phosphate buffered saline (PBS), pH 7.4
    Preservative
    Azide free
    Handling Advice
    Do not freeze.
    Storage
    4 °C
    Storage Comment
    Store at 2-8°C. Do not freeze.
  • Dunn, Boyer, McWilliams, Smith, Hughes: "Mutations in human immunodeficiency virus type 1 reverse transcriptase that make it sensitive to degradation by the viral protease in virions are selected against in patients." in: Virology, Vol. 484, pp. 127-35, (2015) (PubMed).

    Dunn, Boyer, Clark, Hughes: "Mutations in HIV-1 reverse transcriptase cause misfolding and miscleavage by the viral protease." in: Virology, (2013) (PubMed).

    Bartonová, Král, Sieglová, Brynda, Fábry, Horejsí, Kozísek, Sasková, Konvalinka, Sedlácek, Rezácová: "Potent inhibition of drug-resistant HIV protease variants by monoclonal antibodies." in: Antiviral research, Vol. 78, Issue 3, pp. 275-7, (2008) (PubMed).

    OLoughlin, Greene, Matsumura: "Diversification and specialization of HIV protease function during in vitro evolution." in: Molecular biology and evolution, Vol. 23, Issue 4, pp. 764-72, (2006) (PubMed).

    Lescar, Brynda, Rezacova, Stouracova, Riottot, Chitarra, Fabry, Horejsi, Sedlacek, Bentley: "Inhibition of the HIV-1 and HIV-2 proteases by a monoclonal antibody." in: Protein science : a publication of the Protein Society, Vol. 8, Issue 12, pp. 2686-96, (2000) (PubMed).

  • Target
    HIV Protease
    Target Type
    Viral Protein
    Background
    The HIV protease (PR) hydrolyzes polyproteins of HIV virus into functional protein products that are essential for its assembly and subsequent activity. This maturation process occurs as the virion buds from the host cell. HIV protease inhibitors are used in the treatment of patients with AIDS and were considered the first breakthrough in over a decade of AIDS research. HIV protease inhibitors can lower the viral load carried by AIDS patents.,HIV-1 PR, HIV-2 PR
You are here:
Support